Ticker: BAYN.DE

Bayer announces plan to acquire biopharma company Perfuse Therapeutics for up to $2.45 billion, expanding its ophthalmology portfolio with promising glaucoma and diabetic retinopathy drug in phase II trials.

Bayer AG (GER: BAYN) faces a $2.1 billion court ruling over its Roundup herbicide, sparking potential stock volatility. The company plans to appeal, asserting the ruling contradicts scientific consensus. Traders should monitor developments for investment opportunities.